R. A. Teryan
Research Subjects
R. A. Teryan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- K. I. Matrenin
Center for Healthcare Quality Assessment and Control
4 shared publications - Vitaliy Vladimirovich Omelyanovskiy
Center for Healthcare Quality Assessment and Control; Russian Medical Academy of Continuing Professional Education
3 shared publications - A. D. Bagdasarov
Center for Healthcare Quality Assessment and Control; Saint Petersburg State Chemical and Pharmaceutical University
2 shared publications - D. N. Pustovalov
Center for Expertise and Quality Control of Medical Care
2 shared publications - E. O. Kurilovich
Center for Expertise and Quality Control of Medical Care
2 shared publications - Ilya Aleksandrovich Mikhailov
Lomonosov Moscow State University
2 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 215-223
Estimation of the socio-economic burden of obesity in the Russian Federation
Objective : To estimate the direct medical costs associated with the treatment of adult patients with obesity in the Russian Federation, including the costs of pharmacotherapy for obesity, management of comorbidities and hospitalizations due to specific obesity-related complication. Material and methods. A mathematical model was developed to analyze the direct medical costs of pharmacotherapy for obesity and related comorbidities over a 1-year time horizon. The analysis included adults aged 18–69 years with obesity (body mass index (BMI) ≥30 kg/m²); a subgroup of individuals with BMI ≥35 kg/m² was analyzed separately. The target population size was determined using national epidemiological data, stratified by sex, age, and obesity class. The model evaluated the costs of pharmacotherapy for obesity, management of comorbid conditions, and hospitalizations associated with type 2 diabetes mellitus, coronary heart disease, and arterial hypertension. Treatment costs were calculated based on dosing regimens, the State Register of Maximum Selling Prices, and public procurement data; hospitalization costs were estimated using diagnosis-related groups. Results . The estimated number of adults with obesity was 21.64 million, including 5.45 million individuals with BMI ≥35 kg/m². In the modeled scenario of universal drug coverage, annual pharmacotherapy costs were estimated at 3.1 trillion rubles for the overall population and 778 billion rubles for the subgroup with BMI ≥35 kg/m². The estimated number of comorbidity cases was 4.44 million for coronary heart disease, 15.2 million for arterial hypertension, and 7.03 million for type 2 diabetes mellitus. Pharmacotherapy costs for these conditions amounted to 69, 324, and 396 billion rubles, respectively. Annual hospitalization costs were estimated at 377 billion rubles for type 2 diabetes mellitus and 89 billion rubles for coronary heart disease. Conclusion . The management of adults with obesity and comorbid conditions within the Russian healthcare system is associated with substantial direct medical costs. Reducing this burden requires a combination of prevention, early detection, and long-term patient management.
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 215-223
Open AccessEstimation of the socio-economic burden of obesity in the Russian Federation
Objective : To estimate the direct medical costs associated with the treatment of adult patients with obesity in the Russian Federation, including the costs of pharmacotherapy for obesity, management of comorbidities and hospitalizations due to specific obesity-related complication. Material and methods. A mathematical model was developed to analyze the direct medical costs of pharmacotherapy for obesity and related comorbidities over a 1-year time horizon. The analysis included adults aged 18–69 years with obesity (body mass index (BMI) ≥30 kg/m²); a subgroup of individuals with BMI ≥35 kg/m² was analyzed separately. The target population size was determined using national epidemiological data, stratified by sex, age, and obesity class. The model evaluated the costs of pharmacotherapy for obesity, management of comorbid conditions, and hospitalizations associated with type 2 diabetes mellitus, coronary heart disease, and arterial hypertension. Treatment costs were calculated based on dosing regimens, the State Register of Maximum Selling Prices, and public procurement data; hospitalization costs were estimated using diagnosis-related groups. Results . The estimated number of adults with obesity was 21.64 million, including 5.45 million individuals with BMI ≥35 kg/m². In the modeled scenario of universal drug coverage, annual pharmacotherapy costs were estimated at 3.1 trillion rubles for the overall population and 778 billion rubles for the subgroup with BMI ≥35 kg/m². The estimated number of comorbidity cases was 4.44 million for coronary heart disease, 15.2 million for arterial hypertension, and 7.03 million for type 2 diabetes mellitus. Pharmacotherapy costs for these conditions amounted to 69, 324, and 396 billion rubles, respectively. Annual hospitalization costs were estimated at 377 billion rubles for type 2 diabetes mellitus and 89 billion rubles for coronary heart disease. Conclusion . The management of adults with obesity and comorbid conditions within the Russian healthcare system is associated with substantial direct medical costs. Reducing this burden requires a combination of prevention, early detection, and long-term patient management.
- Open Access
- 8 May 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (1) , 86-105
Clinical and economic evaluation of the effectiveness of modern strategies for screening and early diagnosis of cervical cancer in the Russian Federation
Aim. To determine the most appropriate strategy for screening and early diagnosis of cervical cancer in the Russian Federation in terms of clinical (diagnostic) and cost-effectiveness.Materials and methods. To assess the clinical (diagnostic) effectiveness of various screening strategies, a systematic review of publications on studies evaluating the effectiveness of cytological examination and human papillomavirus (HPV) testing for the diagnosis of cervical cancer and its precancerous conditions was conducted. This analysis included publications on the results of studies that assessed the sensitivity and specificity of diagnostic tests used in screening programs. Economic evaluation of the use of various screening strategies was carried out using a mathematical model. The analysis is based on the Markov model of the natural development of oncogenic HPV infection in the absence of screening. Mathematical modeling was performed for a cohort of patients aged 30–64 years inclusive, who have not undergone hysterectomy and who initially have no symptoms of cervical cancer. Clinical and economic analysis was performed from the perspective of the Moscow healthcare system and taking into account the time horizon of 40 years. In a cost-effectiveness analysis, the costs and effectiveness of three screening strategies: conventional cytology followed by triage (p16 and Ki-67 expression detection, CINtec® technology); HPV testing (Cobas HPV®) followed by CINtec® triage and conventional cytology; co-testing – conventional cytology + HPV testing (Cobas HPV®) followed by CINtec® triage, were compared with a strategy of using conventional cytology alone.Results. The article presents the results of the evaluation of the clinical (diagnostic) efficiency of HPV testing compared with cytological studies, traditional cytological study compared with other diagnostic methods, HPV testing compared with other diagnostic methods, co-testing compared with cytological study only and the use of new biomarkers for the diagnosis of cervical neoplasia, including biomarkers for the detection of p16 and Ki-67 expression. Also, the analysis of cervical cancer screening programs in foreign countries, the efficiency of organized screening programs and the analysis of the cost-effectiveness of various screening strategies in Moscow are conducted. It has been established that there is no single model of cervical cancer screening in the world that would be suitable for every country. In most countries, there is a clear trend towards the transition from cytological testing to testing based on the detection of HPV DNA in certain age cohorts of women. It is also worth noting that not all developed countries have switched from opportunistic to organized cervical cancer screening. Based on the results of the clinical and economic study, it was determined that all the screening strategies studied are cost-effective, and the “Co-testing” screening strategy is the most effective in terms of reducing the number of cases of cervical cancer and deaths from cervical cancer.Conclusion. The co-testing strategy, including the use of a biomarker to detect the expression of p16 and Ki-67, should be considered as the main one for conducting screening and early diagnosis programs for cervical cancer in the Russian Federation.
- 8 May 2025
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (1) , 86-105
Open AccessClinical and economic evaluation of the effectiveness of modern strategies for screening and early diagnosis of cervical cancer in the Russian Federation
Aim. To determine the most appropriate strategy for screening and early diagnosis of cervical cancer in the Russian Federation in terms of clinical (diagnostic) and cost-effectiveness.Materials and methods. To assess the clinical (diagnostic) effectiveness of various screening strategies, a systematic review of publications on studies evaluating the effectiveness of cytological examination and human papillomavirus (HPV) testing for the diagnosis of cervical cancer and its precancerous conditions was conducted. This analysis included publications on the results of studies that assessed the sensitivity and specificity of diagnostic tests used in screening programs. Economic evaluation of the use of various screening strategies was carried out using a mathematical model. The analysis is based on the Markov model of the natural development of oncogenic HPV infection in the absence of screening. Mathematical modeling was performed for a cohort of patients aged 30–64 years inclusive, who have not undergone hysterectomy and who initially have no symptoms of cervical cancer. Clinical and economic analysis was performed from the perspective of the Moscow healthcare system and taking into account the time horizon of 40 years. In a cost-effectiveness analysis, the costs and effectiveness of three screening strategies: conventional cytology followed by triage (p16 and Ki-67 expression detection, CINtec® technology); HPV testing (Cobas HPV®) followed by CINtec® triage and conventional cytology; co-testing – conventional cytology + HPV testing (Cobas HPV®) followed by CINtec® triage, were compared with a strategy of using conventional cytology alone.Results. The article presents the results of the evaluation of the clinical (diagnostic) efficiency of HPV testing compared with cytological studies, traditional cytological study compared with other diagnostic methods, HPV testing compared with other diagnostic methods, co-testing compared with cytological study only and the use of new biomarkers for the diagnosis of cervical neoplasia, including biomarkers for the detection of p16 and Ki-67 expression. Also, the analysis of cervical cancer screening programs in foreign countries, the efficiency of organized screening programs and the analysis of the cost-effectiveness of various screening strategies in Moscow are conducted. It has been established that there is no single model of cervical cancer screening in the world that would be suitable for every country. In most countries, there is a clear trend towards the transition from cytological testing to testing based on the detection of HPV DNA in certain age cohorts of women. It is also worth noting that not all developed countries have switched from opportunistic to organized cervical cancer screening. Based on the results of the clinical and economic study, it was determined that all the screening strategies studied are cost-effective, and the “Co-testing” screening strategy is the most effective in terms of reducing the number of cases of cervical cancer and deaths from cervical cancer.Conclusion. The co-testing strategy, including the use of a biomarker to detect the expression of p16 and Ki-67, should be considered as the main one for conducting screening and early diagnosis programs for cervical cancer in the Russian Federation.
- 6 March 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- No. 1
Cost-effectiveness analysis of bariatric surgery in obese patients
Ratio Objective. To perform cost-effectiveness analysis of bariatric surgery in adult obese patients compared to standard drug therapy; to analyze the impact of bariatric surgery on national budget system from the perspective of the healthcare system and the state. Material and methods. The mathematical model assessed clinical and economic effectiveness of two treatment methods: bariatric surgery vs. standard drug therapy in obese adult patients with BMI ≥40 kg/m2 regardless of comorbidities and obese adults with BMI ≥35 kg/m2 and comorbidities (diabetes mellitus type 2, joint diseases, obstructive sleep apnea syndrome). The model was used to predict all-cause mortality. Direct costs of treating obesity, other direct and indirect costs following losses in gross domestic product due to mortality of working-age population, as well as total costs and break-even point, incremental cost-effectiveness ratio (ICER) were calculated. The budget impact of bariatric surgery was analyzed. Results. We found higher cost and clinical efficacy of bariatric surgery compared to standard drug therapy for obesity. After bariatric surgery, mortality was lower by 20.65% in the first year and 45.69% in the seventh year compared to standard drug therapy. Bariatric surgery is characterized by higher costs related to surgical intervention. The last ones occurred at the beginning of modeling. Cost of therapy increased over time and spread over the entire modeling horizon. The cost per case of bariatric surgery was 303.574.00 rubles, standard drug therapy for obesity — 73.006.13 rubles per year, and these values increased over time. In turn, the total costs, including the costs of treating obesity, other direct costs, as well as indirect costs were significantly lower in the bariatric surgery group. In long-term period, this significantly reduced economic burden of the state on the treatment of morbid obesity by 30.84% and 63.12% without discounting over a 5-year and 7-year horizon, respectively. Taking into account obesity treatment cost, other direct and indirect costs, we achieved break-even point at the 86th, 56th and 45th month of modeling, respectively. Conclusion. Bariatric surgery in patients with morbid obesity can reduce the number of deaths. Additional one-time direct costs will be compensated over time due to higher cumulative cost of drug therapy, other direct and indirect costs for patients receiving drug therapy with possible break-even point after 45—86 months.
- 6 March 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- No. 1
Cost-effectiveness analysis of bariatric surgery in obese patients
Ratio Objective. To perform cost-effectiveness analysis of bariatric surgery in adult obese patients compared to standard drug therapy; to analyze the impact of bariatric surgery on national budget system from the perspective of the healthcare system and the state. Material and methods. The mathematical model assessed clinical and economic effectiveness of two treatment methods: bariatric surgery vs. standard drug therapy in obese adult patients with BMI ≥40 kg/m2 regardless of comorbidities and obese adults with BMI ≥35 kg/m2 and comorbidities (diabetes mellitus type 2, joint diseases, obstructive sleep apnea syndrome). The model was used to predict all-cause mortality. Direct costs of treating obesity, other direct and indirect costs following losses in gross domestic product due to mortality of working-age population, as well as total costs and break-even point, incremental cost-effectiveness ratio (ICER) were calculated. The budget impact of bariatric surgery was analyzed. Results. We found higher cost and clinical efficacy of bariatric surgery compared to standard drug therapy for obesity. After bariatric surgery, mortality was lower by 20.65% in the first year and 45.69% in the seventh year compared to standard drug therapy. Bariatric surgery is characterized by higher costs related to surgical intervention. The last ones occurred at the beginning of modeling. Cost of therapy increased over time and spread over the entire modeling horizon. The cost per case of bariatric surgery was 303.574.00 rubles, standard drug therapy for obesity — 73.006.13 rubles per year, and these values increased over time. In turn, the total costs, including the costs of treating obesity, other direct costs, as well as indirect costs were significantly lower in the bariatric surgery group. In long-term period, this significantly reduced economic burden of the state on the treatment of morbid obesity by 30.84% and 63.12% without discounting over a 5-year and 7-year horizon, respectively. Taking into account obesity treatment cost, other direct and indirect costs, we achieved break-even point at the 86th, 56th and 45th month of modeling, respectively. Conclusion. Bariatric surgery in patients with morbid obesity can reduce the number of deaths. Additional one-time direct costs will be compensated over time due to higher cumulative cost of drug therapy, other direct and indirect costs for patients receiving drug therapy with possible break-even point after 45—86 months.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (4)
Sodium-glucose cotransporter 2 inhibitors in chronic heart failure: impact on life expectancy in the Russian population
Objective. To assess the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors in chronic heart failure (CHF) on life expectancy in the Russian population. Material and methods. We used the Markov model to estimate mortality from CHF. The model considered 2 scenarios: 1) baseline scenario (standard treatment of CHF); 2) modeled scenario (treatment with SGLT2 inhibitors (dapagliflozin or empagliflozin) according to indications). Life tables were constructed to estimate life expectancy in patients with CHF and population of the Russian Federation as a whole. We estimated life expectancy increment as the difference between life expectancies in both scenarios. We performed deterministic analysis of the model’s sensitivity to variability of the main parameters. Results. By 2030, empagliflozin and dapagliflozin therapy for CHF can increase life expectancy of the Russian population by 0.085 or 0.177 years, respectively. Analysis of the model’s sensitivity to variability of the main parameters showed that overall mortality under drug therapy has the greatest impact on the modeling results. In addition, life expectancy increment depends on age of diagnosing the disease. Greater life expectancy increment is expected in younger patients undergoing therapy for CHF. Conclusion. The modeled therapy with SGLT2 inhibitors (dapagliflozin and empagliflozin) for chronic heart failure increases life expectancy in the Russian Federation. Similar models for assessing the effectiveness of treatment of diseases significantly contributing to mortality can be used to justify regional and federal management decisions in healthcare.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (4)
Sodium-glucose cotransporter 2 inhibitors in chronic heart failure: impact on life expectancy in the Russian population
Objective. To assess the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors in chronic heart failure (CHF) on life expectancy in the Russian population. Material and methods. We used the Markov model to estimate mortality from CHF. The model considered 2 scenarios: 1) baseline scenario (standard treatment of CHF); 2) modeled scenario (treatment with SGLT2 inhibitors (dapagliflozin or empagliflozin) according to indications). Life tables were constructed to estimate life expectancy in patients with CHF and population of the Russian Federation as a whole. We estimated life expectancy increment as the difference between life expectancies in both scenarios. We performed deterministic analysis of the model’s sensitivity to variability of the main parameters. Results. By 2030, empagliflozin and dapagliflozin therapy for CHF can increase life expectancy of the Russian population by 0.085 or 0.177 years, respectively. Analysis of the model’s sensitivity to variability of the main parameters showed that overall mortality under drug therapy has the greatest impact on the modeling results. In addition, life expectancy increment depends on age of diagnosing the disease. Greater life expectancy increment is expected in younger patients undergoing therapy for CHF. Conclusion. The modeled therapy with SGLT2 inhibitors (dapagliflozin and empagliflozin) for chronic heart failure increases life expectancy in the Russian Federation. Similar models for assessing the effectiveness of treatment of diseases significantly contributing to mortality can be used to justify regional and federal management decisions in healthcare.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Evaluation of clinical efficacy and efficiency of new anticoagulants and sodium-glucose cotransporter 2 inhibitors in patients with coronary artery disease and concomitant cardiovascular diseases
Objective. To evaluate clinical efficacy and efficiency of new oral anticoagulants (NOACs) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with coronary artery disease and concomitant cardiovascular diseases in national healthcare system. Material and methods. The mathematical model assessed clinical efficacy and efficiency of 2 groups of drugs: 1) NOACs (apixaban, dabigatran and rivaroxaban) compared to warfarin in patients with coronary artery disease and atrial fibrillation (AF); 2) SGLT-2 inhibitors (dapagliflozin and empagliflozin) in addition to standard treatment compared to standard treatment without SGLT-2 inhibitors in patients with coronary artery disease and chronic heart failure (CHF) with ejection fraction (EF) <40%. Prediction of all-cause mortality was based on clinical trials after previous systematic searching of appropriate data. We estimated direct medical costs of NOACs and SGLT-2 inhibitors, as well as indirect costs following losses in gross domestic product, cost of prevented death and economic effect per 1 ruble invested. Results. Fewer deaths and higher costs are expected in patients with coronary artery disease and AF receiving NOACs compared to warfarin. The cost of 1 prevented death ranged from 18.75 to 14.63 million rubles. Economic effect per 1 additionally invested ruble for 1, 3 and 7 years was 0.06, 0.124 and 0.267 rubles, respectively. Fewer deaths and higher costs are also assumed in patients with coronary artery disease and CHF (EF <40%) receiving SGLT-2 inhibitors+standard treatment compared to standard treatment alone. The cost of 1 prevented death ranged from 7.93 to 3.81 million rubles. Economic effect per 1 additionally invested ruble for 1, 3 and 7 years was 0.132, 0.271 and 0.583 rubles, respectively. Conclusion. New anticoagulants in patients with coronary artery disease and atrial fibrillation, as well as SGLT-2 inhibitors in patients with chronic heart failure and EF <40% can reduce mortality. Necessary additional costs will be partially offset by lower indirect costs associated with losses in gross domestic product. The cost of prevented death is lower in cohort of patients with coronary artery disease and chronic heart failure receiving SGLT-2 inhibitors compared to patients with coronary artery disease and atrial fibrillation receiving new anticoagulants. Economic effect per 1 ruble invested for SGLT-2 inhibitors exceeds the effect for new anticoagulants.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (3)
Evaluation of clinical efficacy and efficiency of new anticoagulants and sodium-glucose cotransporter 2 inhibitors in patients with coronary artery disease and concomitant cardiovascular diseases
Objective. To evaluate clinical efficacy and efficiency of new oral anticoagulants (NOACs) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with coronary artery disease and concomitant cardiovascular diseases in national healthcare system. Material and methods. The mathematical model assessed clinical efficacy and efficiency of 2 groups of drugs: 1) NOACs (apixaban, dabigatran and rivaroxaban) compared to warfarin in patients with coronary artery disease and atrial fibrillation (AF); 2) SGLT-2 inhibitors (dapagliflozin and empagliflozin) in addition to standard treatment compared to standard treatment without SGLT-2 inhibitors in patients with coronary artery disease and chronic heart failure (CHF) with ejection fraction (EF) <40%. Prediction of all-cause mortality was based on clinical trials after previous systematic searching of appropriate data. We estimated direct medical costs of NOACs and SGLT-2 inhibitors, as well as indirect costs following losses in gross domestic product, cost of prevented death and economic effect per 1 ruble invested. Results. Fewer deaths and higher costs are expected in patients with coronary artery disease and AF receiving NOACs compared to warfarin. The cost of 1 prevented death ranged from 18.75 to 14.63 million rubles. Economic effect per 1 additionally invested ruble for 1, 3 and 7 years was 0.06, 0.124 and 0.267 rubles, respectively. Fewer deaths and higher costs are also assumed in patients with coronary artery disease and CHF (EF <40%) receiving SGLT-2 inhibitors+standard treatment compared to standard treatment alone. The cost of 1 prevented death ranged from 7.93 to 3.81 million rubles. Economic effect per 1 additionally invested ruble for 1, 3 and 7 years was 0.132, 0.271 and 0.583 rubles, respectively. Conclusion. New anticoagulants in patients with coronary artery disease and atrial fibrillation, as well as SGLT-2 inhibitors in patients with chronic heart failure and EF <40% can reduce mortality. Necessary additional costs will be partially offset by lower indirect costs associated with losses in gross domestic product. The cost of prevented death is lower in cohort of patients with coronary artery disease and chronic heart failure receiving SGLT-2 inhibitors compared to patients with coronary artery disease and atrial fibrillation receiving new anticoagulants. Economic effect per 1 ruble invested for SGLT-2 inhibitors exceeds the effect for new anticoagulants.
- Open Access
- 21 April 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (1) , 17-34
Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program
Objective: to evaluate the clinical and economic feasibility of expanding the preferential drug provision (PDP) program for adult patients at very high cardiovascular (CV) risk, including those who have not reached lipid targets on statin therapy, by increasing the frequency of use of ezetimibe, alirocumab, evolocumab and inclisiran used in combination with statins, compared with current PDP practice (use of atorvastatin, simvastatin and minimal use of other drugs).Material and methods. A Markov model was constructed to characterize the development of atherosclerotic heart disease in patients with very high CV risk and to suggest a consistent change in hypolipidemic therapy if it is ineffective. The model considered patients' compliance to drug therapy over time and the factor of non-prescription of any treatment. The modeling horizon was 30 years, and the model cycle was 1 year. The outcomes used were quality-adjusted life years (QALY), life years gained (LYG), and probabilities of various individual and combined CV events. The baseline modeling scenario was to increase the frequency of рroprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors’ prescriptions. In addition, alternative scenarios were modeled that included prescription of highly effective lipid-lowering therapy for all patients who had not reached target low-density lipoprotein cholesterol (LDL-C) on statin therapy, and the scenario with 100% compliance to statin therapy.Results. In comparison with current practice of treatment of patients with very high CV risk, clinical and economic modeling showed a decrease in the incidence of combined outcomes (combined CV events – by 8%, extended combined CV events – by 9%) and individual CV events (heart attack – by 4%, stroke – by 3%, unstable angina – by 2%, revascularization – by 3%) in the baseline scenario. In scenarios of prescribing PCSK9 inhibitors and inclisiran to all patients who have not reached target values of LDL-C on statin therapy, the frequency of individual events ranged from 4% to 8%. In the scenario, which also implies 100% drug compliance, the reduction was from 8% to 17% compared with current patient management practices, characterized by lower frequency of hypolipidemic drugs, including PCSK9 inhibitors and inclisiran. The incremental cost-effectiveness ratio (ICER) for QALY in the baseline scenario was 3,598,156 rubles, the ICER for LYG was 1,949,393 rubles. When comparing the ICER with willingness-to-pay (WTP) threshold in the Russian Federation (calculated as three times the gross domestic product per capita and in 2022 amounting to 2.8 million rubles per effect unit) the ICER for LYG did not exceed the WTP in all scenarios, while the ICER for QALY exceeded the WTP by 29–44%, depending on the realized scenario.Conclusion. Expanding the PDP program for high CV risk patients will have a positive impact on their quality of life and life expectancy, as well as significantly reduce the likelihood of acute CV events. Comparison of ICER with estimated WTP suggests that expansion of the PBP program is a cost-effective organizational technology according to LYG criterion, but not according to the QALY criterion.
- 21 April 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (1) , 17-34
Open AccessCost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program
Objective: to evaluate the clinical and economic feasibility of expanding the preferential drug provision (PDP) program for adult patients at very high cardiovascular (CV) risk, including those who have not reached lipid targets on statin therapy, by increasing the frequency of use of ezetimibe, alirocumab, evolocumab and inclisiran used in combination with statins, compared with current PDP practice (use of atorvastatin, simvastatin and minimal use of other drugs).Material and methods. A Markov model was constructed to characterize the development of atherosclerotic heart disease in patients with very high CV risk and to suggest a consistent change in hypolipidemic therapy if it is ineffective. The model considered patients' compliance to drug therapy over time and the factor of non-prescription of any treatment. The modeling horizon was 30 years, and the model cycle was 1 year. The outcomes used were quality-adjusted life years (QALY), life years gained (LYG), and probabilities of various individual and combined CV events. The baseline modeling scenario was to increase the frequency of рroprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors’ prescriptions. In addition, alternative scenarios were modeled that included prescription of highly effective lipid-lowering therapy for all patients who had not reached target low-density lipoprotein cholesterol (LDL-C) on statin therapy, and the scenario with 100% compliance to statin therapy.Results. In comparison with current practice of treatment of patients with very high CV risk, clinical and economic modeling showed a decrease in the incidence of combined outcomes (combined CV events – by 8%, extended combined CV events – by 9%) and individual CV events (heart attack – by 4%, stroke – by 3%, unstable angina – by 2%, revascularization – by 3%) in the baseline scenario. In scenarios of prescribing PCSK9 inhibitors and inclisiran to all patients who have not reached target values of LDL-C on statin therapy, the frequency of individual events ranged from 4% to 8%. In the scenario, which also implies 100% drug compliance, the reduction was from 8% to 17% compared with current patient management practices, characterized by lower frequency of hypolipidemic drugs, including PCSK9 inhibitors and inclisiran. The incremental cost-effectiveness ratio (ICER) for QALY in the baseline scenario was 3,598,156 rubles, the ICER for LYG was 1,949,393 rubles. When comparing the ICER with willingness-to-pay (WTP) threshold in the Russian Federation (calculated as three times the gross domestic product per capita and in 2022 amounting to 2.8 million rubles per effect unit) the ICER for LYG did not exceed the WTP in all scenarios, while the ICER for QALY exceeded the WTP by 29–44%, depending on the realized scenario.Conclusion. Expanding the PDP program for high CV risk patients will have a positive impact on their quality of life and life expectancy, as well as significantly reduce the likelihood of acute CV events. Comparison of ICER with estimated WTP suggests that expansion of the PBP program is a cost-effective organizational technology according to LYG criterion, but not according to the QALY criterion.
- Open Access
- 21 April 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (1) , 60-69
Clinical approbation today: analysis of current problems and solutions
Objective: description of the current problems concerning the development and conducting of a protocol of clinical approbation (CA) of methods of prevention, diagnosis, treatment and rehabilitation to optimize the implementation of innovative medical technologies in practical health care through CA.Material and methods. The review of the legislative framework governing CA and analysis of the proceedings of CA issues strategic session were carried out, management decisions to improve the effectiveness of CA were proposed. Analysis of legal acts stipulating the notion and status of CA was performed. The study included orders of the Ministry of Health of the Russian Federation, which established regulations on the organization of CA, the CA protocol templates, etc. Methodological materials, review articles on the organization of health care in the Russian Federation selected from various open sources were studied. The basis for making management decisions on improving the quality of CA procedure was formed by the participants of the CA issues strategic session which had been initiated by the Center for Healthcare Quality Assessment and Control.Results. Based on the results of the strategic session and the analysis of legal acts, current issues related to CA regulation, such as lack of СА coordination and research publications, poor methodological quality of clinical and economic evaluations within CA, promotion of innovation through CA were identified. The developed managerial decisions on improvement of CA and promotion of innovations in practical health care were presented.Conclusion. Current legal acts regulating CA activities should be updated with a view to establishing a transparent system of clinical and economic evaluations of new and innovative methods for making an informed decision to include them in clinical guidelines and routine clinical practice. It is proposed to legally assign the functions of CA coordinator to the federal medical development organizations. Regarding the promotion of innovative technologies in practical health care, it is advisable to create a system for the introduction of innovations, including taking into account conducting CA.
- 21 April 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (1) , 60-69
Open AccessClinical approbation today: analysis of current problems and solutions
Objective: description of the current problems concerning the development and conducting of a protocol of clinical approbation (CA) of methods of prevention, diagnosis, treatment and rehabilitation to optimize the implementation of innovative medical technologies in practical health care through CA.Material and methods. The review of the legislative framework governing CA and analysis of the proceedings of CA issues strategic session were carried out, management decisions to improve the effectiveness of CA were proposed. Analysis of legal acts stipulating the notion and status of CA was performed. The study included orders of the Ministry of Health of the Russian Federation, which established regulations on the organization of CA, the CA protocol templates, etc. Methodological materials, review articles on the organization of health care in the Russian Federation selected from various open sources were studied. The basis for making management decisions on improving the quality of CA procedure was formed by the participants of the CA issues strategic session which had been initiated by the Center for Healthcare Quality Assessment and Control.Results. Based on the results of the strategic session and the analysis of legal acts, current issues related to CA regulation, such as lack of СА coordination and research publications, poor methodological quality of clinical and economic evaluations within CA, promotion of innovation through CA were identified. The developed managerial decisions on improvement of CA and promotion of innovations in practical health care were presented.Conclusion. Current legal acts regulating CA activities should be updated with a view to establishing a transparent system of clinical and economic evaluations of new and innovative methods for making an informed decision to include them in clinical guidelines and routine clinical practice. It is proposed to legally assign the functions of CA coordinator to the federal medical development organizations. Regarding the promotion of innovative technologies in practical health care, it is advisable to create a system for the introduction of innovations, including taking into account conducting CA.